Showing results (131-140 of 140) with videos related to
Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.Cancer Cell|April 24, 2026
Anticancer activity of RAS-GTP inhibition in cholangiocarcinomaRodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, et al.Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021David S Ettinger, Douglas E Wood, Dara L Aisner, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2023
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyDavid S Ettinger, Douglas E Wood, James Stevenson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S Ettinger, Douglas E Wood, Dara L Aisner, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023David S Ettinger, Douglas E Wood, Dara L Aisner, et al.The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.Pageof 14